Lindera aggregata (also known as Wu Yao in traditional Chinese medicine) has a long history of use in East Asian herbal medicine. Traditionally, it is primarily utilized for its effects on the digestive and urinary systems, specifically to promote qi circulation, relieve pain, and address issues such as abdominal distension, coldness, and frequent urination. In the context of hepatitis, Lindera aggregata is sometimes included in complex herbal formulas prescribed for liver-related disorders, including hepatitis, within traditional Chinese medicine (TCM) frameworks. The rationale is rooted in the herb's purported ability to "move qi" and alleviate stagnation, which TCM often associates with liver dysfunction.

However, direct scientific evidence supporting Lindera aggregata's efficacy for hepatitis is limited. While some pharmacological studies have indicated that extracts of Lindera aggregata possess hepatoprotective and anti-inflammatory properties in animal models, robust clinical trials in humans with hepatitis are lacking. Most modern research focuses on its analgesic, anti-inflammatory, and antispasmodic effects, not specifically on hepatitis treatment. Thus, the use of Lindera aggregata for hepatitis is justified primarily by traditional practice, with only preliminary scientific evidence suggesting potential benefits. The current evidence level is low, and further rigorous studies are needed to confirm its efficacy and safety for hepatitis.